From February to April of 2020, we conducted a 2‐center clinical trial by recruiting 26 patients with severe COVID‐19 to receive treatment with a single dose of 7.5 mg/kg bevacizumab, an anti‐VEGF neutralizing antibody.[33] The recruitment criteria include partial arterial oxygen pressure to fraction of inspiration O2 ratio (PaO2/FiO2) > 100 mmHg and ≤300 mmHg and diffuse pneumonia confirmed by chest imaging. The gene discussed is VEGFA; the disease is COVID-19.